Compare Paychex, Inc. (PAYX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs GeneDx Holdings Corp — how do they compare? Paychex, Inc. trades at $104.06 (market cap $37.19B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Paychex, Inc. is far larger — about 18.4× GeneDx Holdings Corp's market cap, and Paychex, Inc. pays a 4.56% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and GeneDx Holdings Corp for 19 Days on average.
| PAYX | WGS | |
|---|---|---|
Market Cap | $37.19B | $2.02B |
Volume | 3,344,316 | 734,640 |
Sector | Industrials | Health |
52-Week High | $128.59 | $167.51 |
52-Week Low | $85.57 | $34.51 |
Typical Hold Time | 56 Days | 19 Days |
Enterprise Value | $40.87B | $2.05B |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $103.98, up 2.39% with a bullish technical signal despite mixed indicators. The company demonstrates strong fundamentals with consistent earnings beats, 27.35% net margins, and robust profitability metrics. Recent news highlights investor concerns about dividend sustainability despite solid Q1 2027 results showing 6% revenue growth and double-digit earnings increases driven by PEO and insurance segments.
Outlook remains cautiously optimistic with a $111 consensus price target offering 6.8% upside. Key risks include labor market sensitivity and competitive pressures, while opportunities lie in AI integration and PEO growth. The stock presents a balanced risk-reward profile with dividend stability supporting investor returns.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
